PDCD1 and hepatocellular carcinoma: According to another single-center retrospective study, TACE and lenvatinib plus PD-1 inhibitors showed prolonged OS (16.9 months vs. 12.1 months), PFS (7.3 months vs. 4.0 months) and better ORR (56.1% vs. 32.5%), DCR (85.4% vs. 62.5%) than TACE plus lenvatinib in advanced HCC, which was consistent with our results [21].